Compare Ecopetrol SA (EC) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecopetrol SA vs Tango Therapeutics Inc. — how do they compare? Ecopetrol SA trades at $17.92 (market cap $33.52B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Ecopetrol SA is far larger — about 8.9× Tango Therapeutics Inc.'s market cap, and Ecopetrol SA pays a 3.71% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ecopetrol SA for 84 Days and Tango Therapeutics Inc. for 0 Days on average.
| EC | TNGX | |
|---|---|---|
Market Cap | $33.52B | $3.75B |
Volume | 1,602,222 | 9,619,106 |
Sector | Energy | Health |
52-Week High | $18.26 | $32.90 |
52-Week Low | $8.61 | $7.50 |
Typical Hold Time | 84 Days | 0 Days |
Enterprise Value | $62.13B | $2.77B |
Dividend Yield | 3.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ecopetrol (EC) trades at $17.90, up 3.89% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. Revenue has declined from $159.61T in 2022 to $119.69T in 2025, with net income margin falling to 8.76%. Recent management changes and board appointments signal corporate transformation efforts, while analyst consensus is cautious with a 'Reduce' rating and $16.85 price target.
The stock faces headwinds from declining profitability and revenue, offset by low valuation multiples (P/E 8.27, EV/EBITDA 4). Risks include political influence, corruption probes, and oil price volatility. Upside depends on execution under new leadership and stabilization of financials, but current sentiment remains neutral to bearish amid operational challenges.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Ecopetrol SA
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
